https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/940565/Information_for_Healthcare_Professionals_on_Pfizer_BioNTech_COVID-19_vaccine.pdf Enkele opvallende passages ! This medicinal product does not have a UK marketing authorisation but has been given authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines & Healthcare products Regulatory Agency for active immunization to prevent COVID-19 disease caused by SARS-CoV-2 virus in individuals aged 16 years of age and over. Active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. No data are available on the use of COVID-19 mRNA Vaccine BNT162b2 in persons that have previously received a full or partial vaccine series with another COVID-19 vaccine. Interaction with other medicinal products and other forms of interaction No interaction studies have been performed. Concomitant administration of COVID-19 mRNA Vaccine BNT162b2 with other vaccines has not been studied Breast-feeding It is unknown whether COVID-19 mRNA Vaccine BNT162b2 is excreted in human milk. A risk to the newborns/infants cannot be excluded. COVID-19 mRNA Vaccine BNT162b2 should not be used during breast-feeding. Fertility It is unknown whether COVID-19 mRNA Vaccine BNT162b2 has an impact on fertility. It allows continued monitoring of the benefit/risk balance of the medicinal product. The nucleoside-modified messenger RNA in COVID-19 mRNA Vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARS- CoV-2 S antigen. The vaccine elicits both neutralizing antibody and cellular immune responses to the spike (S) antigen, which may contribute to protection against COVID-19 disease. Confirmed cases were determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and at least 1 symptom consistent with COVID-19 disease*. There were 8 confirmed COVID-19 cases identified in the COVID-19 mRNA Vaccine group and 162 cases in the placebo group, respectively. In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. MARKETING AUTHORISATION HOLDER Not applicable. MARKETING AUTHORISATION NUMBER(S) Not applicable. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Not applicable.